A SynNotch receptor that detects a specific priming antigen, such as the heterogeneous but tumor-specific EGFRvIII or the CNS tissue-specific antigen myelin oligodendrocyte glycoprotein (MOG), can be used to locally induce expression of a CAR as demonstrated by Choe et al. This enables controlled tumor cell killing by targeting antigens that are homogeneous but not absolutely tumor-specific [165]. Here, MOG is linked to neoplasm.